

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096432 A1

(51) International Patent Classification:

A61K 38/16 (2006.01) C07K 14/47 (2006.01)
A61P 13/12 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2024/053399

(22) International Filing Date:

29 October 2024 (29.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/546,329 30 October 2023 (30.10.2023) US
63/700,966 30 September 2024 (30.09.2024) US

(71) Applicant: **Q32 BIO INC.** [US/US]; 830 Winter Street,
Waltham, MA 02451 (US).

(72) Inventors: **CAMPAGNA, Jason**; c/o Q32 Bio Inc., 830
Winter Street, Waltham, MA 02451 (US). **VIOLETTE,
Shelia, Marie**; c/o Q32 Bio Inc., 830 Winter Street,
Waltham, MA 02451 (US). **WU, Hong**; c/o Q32 Bio Inc.,
830 Winter Street, Waltham, MA 02451 (US).

(74) Agent: **LU, Yu** et al.; McCarter & English, LLP, 265
Franklin Street, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF ANCA-ASSOCIATED VASCULITIS

(57) Abstract: Provided are compounds, compositions and methods for treating ANCA-Associated Vasculitis (AA V) in patients in need thereof, the method comprising administering an effective amount of a composition comprising a fusion protein construct comprising: an antibody that specifically binds to complement protein 3d (c3d), and two complement modulator polypeptides each comprising a biologically active fragment of factor H.

WO 2025/096432 A1